Radiopharmaceuticals remains a hot topic in 2026, with continued investment from both big and mid-sized pharma, and private equity in the last twelve months. Will Johnson, engagement manager, Lakshiv Dhingra, clinical fellow, and Victor Chua, partner, at Mansfield Advisors outline key developments and potential asset classes for private equity investors considering the sector Radiopharmaceuticals are…
Membership Required
You must be a HM Subscriber to view this content.